Announcements Trials
Browse Landscape

Phase

Phase 2 191Phase 3 77Phase 1 55Phase 1/2 50Phase 2/3 8Phase NA 7Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 17Thoracic 6Tumor-Agnostic 3Head & Neck 3Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Zoledronic Acid 15enzalutamide 10Leuprolide 9Goserelin 8bicalutamide 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Triptorelin Pamoate 6Prednisone 6Nivolumab 6Abiraterone Acetate 6luprolide acetate gel depot 5Sunitinib 5Magnetic Resonance Spectroscopy 5Everolimus 5Dutasteride 5Specimen Handling 4Sodium Chloride 4Propofol 4Prednisolone 4Androgen Antagonists 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4pazopanib 3fluciclovine F-18 3darolutamide 3cabazitaxel 3Trimethoprim, Sulfamethoxazole Drug Combination 3Rocuronium 3Mitomycin 3Midazolam 3Flutamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Docetaxel × Genitourinary × Clear all
NCT00280098 2009-12-07

Docetaxel in the Treatment of Hormone Refractory Prostate Cancer

Sanofi

Phase 4 Completed
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡